\-\ Texto\\:\\ \ \(0\)\
\-\ none\\.\ \(8\)\
\-\ this\\ patient\\ was\\ stage\\ 1\\ sarcoid\\ and\\ was\\ began\\ on\\ a\\ steroid\\ regimen\\ with\\ radiographic\\ followup\\.\ \(0\)\
\-\ bilateral\\ and\\ symmetric\\ hilar\\ adenopathy\ \(1\)\
\-\ pulmonary\\ sarcoidosis\ \(3\)\
\-\ sarcoid\ \(163\)\
\-\ lymphoma\\,\\ hodgkin\\â\\€\\™s\\ and\\ nhl\ \(0\)\
\-\ castleman\\â\\€\\™s\\ disease\ \(0\)\
\-\ metastic\\ disease\ \(2\)\
\-\ severe\\ infection\ \(0\)\
\-\ 32\\ yo\\ man\\ with\\ shortness\\ of\\ breath\\.\ \(1\)\
\-\ this\\ is\\ a\\ good\\ example\\ of\\ stage\\ 1\\ sarcoid\\,\\ bilateral\\ symmetric\\ hilar\\ adenopathy\\.\\ \\ the\\ patient\\â\\€\\™s\\ shortness\\ of\\ breath\\ resolved\\ with\\ bronchodilators\\ and\\ is\\ scheduled\\ for\\ continued\\ radiographic\\ followup\\ and\\ was\\ put\\ on\\ a\\ steroid\\ regimen\\.\ \(0\)\
\-\ stages\\ based\\ on\\ cxr\\:\ \(0\)\
\-\ stage\\ 0\\:\\ normal\\ film\\,\\ 10\\%\ \(0\)\
\-\ stage\\ 1\\:\\ adenopathy\\,\\ 50\\%\ \(0\)\
\-\ \\	symmetric\\ hilar\\ adenopathy\ \(0\)\
\-\ \\	paratracheal\\,\\ tracheobronchial\\,\\ and\\ azygos\\ adenpathy\\ is\\ commonly\\ associated\\ with\\ hilar\\ adenopathy\ \(0\)\
\-\ \\	calcification\\,\\ 5\\%\ \(0\)\
\-\ stage\\ 2\\:\\ adenopathy\\ with\\ pulmonary\\ opacities\\,\\ 30\\%\ \(0\)\
\-\ \\	reticulonodular\\ pattern\ \(0\)\
\-\ \\	acinar\\ pattern\\ may\\ coalesce\\ to\\ consolidation\ \(0\)\
\-\ \\	large\\ nodules\\ \\>1cm\\ \\(2\\%\\)\ \(0\)\
\-\ stage\\ 3\\:\\ pulmonary\\ opacities\\ without\\ hilar\\ adenopathy\\,\\ 10\\%\ \(0\)\
\-\ stage\\ 4\\:\\ pulmonary\\ fibrosis\\,\\ upper\\ lobes\\ with\\ bullae\ \(0\)\
\-\ other\\ less\\ common\\ plain\\ film\\ findings\\:\ \(0\)\
\-\ \\	pleural\\ effusion\\,\\ 10\\%\ \(0\)\
\-\ \\	unilateral\\ hilar\\ adenopathy\\,\\ 1\\-3\\%\ \(0\)\
\-\ \\	eggshell\\ calcification\\ of\\ lymph\\ nodes\ \(0\)\
\-\ \\	complications\\ of\\ stage\\ 3\\ include\\ pneumothorax\\ \\(blebs\\,\\ bullae\\)\\ and\\ aspergillus\\ with\\ fungus\\ ball\ \(0\)\
\-\ \\	bronchostenosis\\ with\\ lobar\\/segmental\\ collapse\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adenopathy\\:\\ 0\\.13835938654073607\ \(0\)\
\-\ stage\\:\\ 0\\.1325467065064853\ \(0\)\
\-\ hilar\\:\\ 0\\.11710172309774884\ \(0\)\
\-\ \\%\\:\\ 0\\.0724844012125821\ \(0\)\
\-\ sarcoid\\:\\ 0\\.059791385797134326\ \(0\)\
\-\ bullae\\:\\ 0\\.05834202864698298\ \(0\)\
\-\ symmetric\\:\\ 0\\.053220866430415174\ \(0\)\
\-\ regimen\\:\\ 0\\.04863438655606155\ \(0\)\
\-\ pulmonary\\:\\ 0\\.04539182382218297\ \(0\)\
\-\ steroid\\:\\ 0\\.04101321209783935\ \(0\)\
\-\ opacities\\:\\ 0\\.04053463270251733\ \(0\)\
\-\ adenpathy\\:\\ 0\\.04007053829075681\ \(0\)\
\-\ bronchostenosis\\:\\ 0\\.04007053829075681\ \(0\)\
\-\ lobar\\/segmental\\:\\ 0\\.04007053829075681\ \(0\)\
\-\ 10\\:\\ 0\\.03928123947745787\ \(0\)\
\-\ followup\\:\\ 0\\.03708472705065457\ \(0\)\
\-\ eggshell\\:\\ 0\\.0369198692882116\ \(0\)\
\-\ \\:\\:\\ 0\\.03596328959970298\ \(0\)\
\-\ bronchodilators\\:\\ 0\\.03507684606953813\ \(0\)\
\-\ acinar\\:\\ 0\\.03507684606953813\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.03482763735880167\ \(0\)\
\-\ s\\:\\ 0\\.0334195590970171\ \(0\)\
\-\ shortness\\:\\ 0\\.032683296353528846\ \(0\)\
\-\ nhl\\:\\ 0\\.03192617706699292\ \(0\)\
\-\ metastic\\:\\ 0\\.03192617706699292\ \(0\)\
\-\ blebs\\:\\ 0\\.03192617706699292\ \(0\)\
\-\ tracheobronchial\\:\\ 0\\.031225492158687203\ \(0\)\
\-\ coalesce\\:\\ 0\\.030083153848319444\ \(0\)\
\-\ film\\:\\ 0\\.0298375357748998\ \(0\)\
\-\ pattern\\:\\ 0\\.02969493035519344\ \(0\)\
\-\ radiographic\\:\\ 0\\.02948513083444303\ \(0\)\
\-\ azygos\\:\\ 0\\.02917101432349149\ \(0\)\
\-\ breath\\:\\ 0\\.029046523256812257\ \(0\)\
\-\ aspergillus\\:\\ 0\\.028775508064447716\ \(0\)\
\-\ castleman\\:\\ 0\\.02841167757502255\ \(0\)\
\-\ 1\\-3\\:\\ 0\\.02841167757502255\ \(0\)\
\-\ calcification\\:\\ 0\\.02819805107688299\ \(0\)\
\-\ 1\\:\\ 0\\.02772717774490509\ \(0\)\
\-\ reticulonodular\\:\\ 0\\.027467862280575985\ \(0\)\
\-\ fungus\\:\\ 0\\.027467862280575985\ \(0\)\
\-\ put\\:\\ 0\\.026686724749091173\ \(0\)\
\-\ paratracheal\\:\\ 0\\.024317193278030776\ \(0\)\
\-\ hodgkin\\:\\ 0\\.024177322102272806\ \(0\)\
\-\ 1cm\\:\\ 0\\.024177322102272806\ \(0\)\
\-\ ball\\:\\ 0\\.02341798535380387\ \(0\)\
\-\ stages\\:\\ 0\\.023302904408420734\ \(0\)\
\-\ 0\\:\\ 0\\.023302904408420734\ \(0\)\
\-\ example\\:\\ 0\\.021384747999059938\ \(0\)\
\-\ collapse\\:\\ 0\\.019876668943073553\ \(0\)\
\-\ began\\:\\ 0\\.019667645701065266\ \(0\)\
\-\ scheduled\\:\\ 0\\.019566631442952946\ \(0\)\
\-\ consolidation\\:\\ 0\\.01946781332187837\ \(0\)\
\-\ 32\\:\\ 0\\.019371097874390716\ \(0\)\
\-\ unilateral\\:\\ 0\\.019276397479377795\ \(0\)\
\-\ bilateral\\:\\ 0\\.018852888448313124\ \(0\)\
\-\ resolved\\:\\ 0\\.01883040722502087\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.018234078996514733\ \(0\)\
\-\ 3\\:\\ 0\\.018190686606423086\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.017544051665296535\ \(0\)\
\-\ nodes\\:\\ 0\\.017544051665296535\ \(0\)\
\-\ fibrosis\\:\\ 0\\.01729492331759201\ \(0\)\
\-\ lobes\\:\\ 0\\.01711664734871346\ \(0\)\
\-\ 2\\:\\ 0\\.01672822269555042\ \(0\)\
\-\ continued\\:\\ 0\\.016725999940528345\ \(0\)\
\-\ good\\:\\ 0\\.01662028693069077\ \(0\)\
\-\ cxr\\:\\ 0\\.016391055777841262\ \(0\)\
\-\ nodules\\:\\ 0\\.016102358479103414\ \(0\)\
\-\ \\,\\:\\ 0\\.01599650387147607\ \(0\)\
\-\ lymph\\:\\ 0\\.015679738222475665\ \(0\)\
\-\ complications\\:\\ 0\\.015391694522782077\ \(0\)\
\-\ pleural\\:\\ 0\\.015083409993969527\ \(0\)\
\-\ 30\\:\\ 0\\.01493676971115943\ \(0\)\
\-\ based\\:\\ 0\\.014812228919395274\ \(0\)\
\-\ 50\\:\\ 0\\.014777263712017293\ \(0\)\
\-\ effusion\\:\\ 0\\.014759881455479096\ \(0\)\
\-\ commonly\\:\\ 0\\.01465696110661655\ \(0\)\
\-\ was\\:\\ 0\\.013476511666550273\ \(0\)\
\-\ less\\:\\ 0\\.013154272746921283\ \(0\)\
\-\ \\>\\:\\ 0\\.012905306884857111\ \(0\)\
\-\ disease\\:\\ 0\\.012697614011051855\ \(0\)\
\-\ plain\\:\\ 0\\.012614835057677656\ \(0\)\
\-\ severe\\:\\ 0\\.011951408182118201\ \(0\)\
\-\ yo\\:\\ 0\\.011687961469558009\ \(0\)\
\-\ 5\\:\\ 0\\.01136436555656438\ \(0\)\
\-\ infection\\:\\ 0\\.011290984427603668\ \(0\)\
\-\ lymphoma\\:\\ 0\\.011100902883588571\ \(0\)\
\-\ include\\:\\ 0\\.010896152218319485\ \(0\)\
\-\ 4\\:\\ 0\\.01082259956899566\ \(0\)\
\-\ common\\:\\ 0\\.010164850963438167\ \(0\)\
\-\ on\\:\\ 0\\.009871241077710383\ \(0\)\
\-\ none\\:\\ 0\\.009635088667763666\ \(0\)\
\-\ upper\\:\\ 0\\.009373093206221447\ \(0\)\
\-\ man\\:\\ 0\\.00918605383222727\ \(0\)\
\-\ associated\\:\\ 0\\.00916573891776228\ \(0\)\
\-\ without\\:\\ 0\\.009145514392537092\ \(0\)\
\-\ other\\:\\ 0\\.00895290249410204\ \(0\)\
\-\ this\\:\\ 0\\.008737611030128482\ \(0\)\
\-\ may\\:\\ 0\\.00851967440408238\ \(0\)\
\-\ large\\:\\ 0\\.00849337469014127\ \(0\)\
\-\ findings\\:\\ 0\\.008267440617227088\ \(0\)\
\-\ patient\\:\\ 0\\.007787199371967163\ \(0\)\
\-\ is\\:\\ 0\\.0076676015234280765\ \(0\)\
\-\ \\(\\:\\ 0\\.0065669247840350956\ \(0\)\
\-\ \\)\\:\\ 0\\.006486706291939137\ \(0\)\
\-\ normal\\:\\ 0\\.0060891475209050045\ \(0\)\
\-\ and\\:\\ 0\\.005727559273297859\ \(0\)\
\-\ a\\:\\ 0\\.005408179115708199\ \(0\)\
\-\ with\\:\\ 0\\.004254697312359627\ \(0\)\
\-\ for\\:\\ 0\\.0033141279483759776\ \(0\)\
\-\ of\\:\\ 0\\.002647813654499737\ \(0\)\
\-\ to\\:\\ 0\\.0019412186747408465\ \(0\)\
\-\ \\.\\:\\ 0\\.0008068076385760517\ \(0\)\
\-\ the\\:\\ 0\\.0006284058395619354\ \(0\)\
